CLARK CHRISTOPHER D purchased $11K of RGT
CLARK CHRISTOPHER D (President) purchased 743 shares of ROYCE GLOBAL TRUST, INC. (RGT) at $14.22 on 2026-09-30.
ROYCE GLOBAL TRUST, INC.
No enriched coverage for $RGT in the last 7 days.
CLARK CHRISTOPHER D (President) purchased 743 shares of ROYCE GLOBAL TRUST, INC. (RGT) at $14.22 on 2026-09-30.
Argent BioPharma (ASX:RGT) shares fell about 7.41% intraday on 22 July 2026, with no single disclosed catalyst for the move. The clinical-stage biotech develops candidates including CannEpil, CimetrA, CogniCann and Irnican. In early July 2026, it licensed global CannEpil rights to Splash Beverage Group for about US$5.5m via convertible-note debt forgiveness and royalties.
The article says volatility returned after Trump declared an Iran ceasefire dead, following Iranian strikes on vessels in the Strait of Hormuz and subsequent US air strikes. It notes Brent crude rose above $80/bbl and junior resources stocks rallied. It highlights ASX-listed Argent BioPharma (RGT) up 206% on a US$5.5m CannEpil licensing deal with Splash, and Peregrine Gold (PGD) up 109% and NewPeak Minerals (NPM) up 107% on early gold discoveries.
Recent RGT coverage spans financial news, insider activity and market movers.
In the last 30 days, RGT insiders filed 1 SEC Form 4 transaction — 1 purchase ($11K) and no sales. The most active reporter was CLARK CHRISTOPHER D, President, with 1 filing.
Small insider purchase may signal slight confidence but unlikely to move price.
The article frames the drop as likely trading/dilution-risk driven rather than a specific clinical or regulatory shock.
Deal structure removes financing overhang and shifts development/regulatory burden to Splash, supporting a bullish re-rating for RGT.
The article highlights Royce Global Trust's recent performance and experienced management, suggesting stability and potential for continued value investing. No immediate market-moving events are reported.
The news highlights Royce Global Trust's (RGT) stable investment approach and historical performance, with no immediate catalysts for significant price movement.
AlphAI scores every news story that mentions RGT with an AI model for sentiment and relevance, and aggregates insider trades from ROYCE GLOBAL TRUST, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CLARK CHRISTOPHER D (President) purchased 743 shares of ROYCE GLOBAL TRUST, INC. (RGT) at $14.22 on 2026-09-30.
1 min readArgent BioPharma (ASX:RGT) shares fell about 7.41% intraday on 22 July 2026, with no single disclosed catalyst for the move. The clinical-stage biotech develops candidates including CannEpil, CimetrA, CogniCann and Irnican. In early July 2026, it licensed global CannEpil rights to Splash Beverage Group for about US$5.5m via convertible-note debt forgiveness and royalties.
5 min readThe article says volatility returned after Trump declared an Iran ceasefire dead, following Iranian strikes on vessels in the Strait of Hormuz and subsequent US air strikes. It notes Brent crude rose above $80/bbl and junior resources stocks rallied. It highlights ASX-listed Argent BioPharma (RGT) up 206% on a US$5.5m CannEpil licensing deal with Splash, and Peregrine Gold (PGD) up 109% and NewPeak Minerals (NPM) up 107% on early gold discoveries.
7 min readA closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 65,001 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min readA closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 69,409 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min readNEW YORK, Sept. 25, 2025 /PRNewswire/ -- A closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 63,386 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min readA closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 98,655 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min readA closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 64,166 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min readA closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 73,279 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min readA closed-end fund that invests in global equities using a disciplined value approach Average weekly trading volume of approximately 104,348 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience
2 min read